Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LlcfiledCriticalBayer Healthcare Llc
Priority to MYPI2016001404ApriorityCriticalpatent/MY181129A/en
Publication of MY181129ApublicationCriticalpatent/MY181129A/en
This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain VIII procoagulant activity and have improved pharmacokinetic properties.
MYPI2016001404A2007-05-182007-05-18Site-directed modification of fviii
MY181129A
(en)
Linear and cross-linked high molecular weight polysilanes, polygermanes, and copolymers thereof, compositions containing the same, and methods of making and using such compounds and compositions
Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases